Bolt Biotherapeutics (BOLT) Competitors $0.44 +0.02 (+4.76%) Closing price 03/26/2025 04:00 PM EasternExtended Trading$0.43 -0.01 (-2.27%) As of 03/26/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock BOLT vs. DOMH, FBIO, AGEN, CRIS, SABS, MTEM, AMGN, GILD, VRTX, and REGNShould you be buying Bolt Biotherapeutics stock or one of its competitors? The main competitors of Bolt Biotherapeutics include Dominari (DOMH), Fortress Biotech (FBIO), Agenus (AGEN), Curis (CRIS), SAB Biotherapeutics (SABS), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN). These companies are all part of the "biotechnology" industry. Bolt Biotherapeutics vs. Dominari Fortress Biotech Agenus Curis SAB Biotherapeutics Molecular Templates Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Dominari (NASDAQ:DOMH) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, community ranking, media sentiment, earnings, dividends and risk. Does the MarketBeat Community prefer DOMH or BOLT? Bolt Biotherapeutics received 80 more outperform votes than Dominari when rated by MarketBeat users. CompanyUnderperformOutperformDominariN/AN/ABolt BiotherapeuticsOutperform Votes8063.49% Underperform Votes4636.51% Do insiders and institutionals have more ownership in DOMH or BOLT? 42.5% of Dominari shares are owned by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 33.0% of Dominari shares are owned by company insiders. Comparatively, 30.9% of Bolt Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, DOMH or BOLT? Dominari has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Is DOMH or BOLT more profitable? Dominari has a net margin of -180.22% compared to Bolt Biotherapeutics' net margin of -665.56%. Dominari's return on equity of -32.89% beat Bolt Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dominari-180.22% -32.89% -29.47% Bolt Biotherapeutics -665.56%-69.46%-48.55% Does the media prefer DOMH or BOLT? In the previous week, Bolt Biotherapeutics had 12 more articles in the media than Dominari. MarketBeat recorded 13 mentions for Bolt Biotherapeutics and 1 mentions for Dominari. Dominari's average media sentiment score of 1.87 beat Bolt Biotherapeutics' score of 0.21 indicating that Dominari is being referred to more favorably in the media. Company Overall Sentiment Dominari Very Positive Bolt Biotherapeutics Neutral Do analysts recommend DOMH or BOLT? Bolt Biotherapeutics has a consensus price target of $1.13, suggesting a potential upside of 155.68%. Given Bolt Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Bolt Biotherapeutics is more favorable than Dominari.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dominari 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Bolt Biotherapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher valuation & earnings, DOMH or BOLT? Dominari has higher revenue and earnings than Bolt Biotherapeutics. Dominari is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDominari$12.59M4.35-$22.88M-$3.87-1.30Bolt Biotherapeutics$9.78M1.72-$69.20M-$1.71-0.26 SummaryDominari beats Bolt Biotherapeutics on 9 of the 16 factors compared between the two stocks. Remove Ads Get Bolt Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BOLT vs. The Competition Export to ExcelMetricBolt BiotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.84M$6.91B$5.63B$8.15BDividend YieldN/A2.73%4.55%4.00%P/E Ratio-0.267.1124.4719.08Price / Sales1.72226.93385.2994.58Price / CashN/A65.6738.1634.64Price / Book0.156.486.954.36Net Income-$69.20M$142.41M$3.20B$247.23M7 Day Performance6.05%-3.39%-2.42%-0.61%1 Month Performance-4.35%-5.34%2.18%-5.12%1 Year Performance-63.03%-7.01%12.85%3.60% Bolt Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BOLTBolt Biotherapeutics3.4932 of 5 stars$0.44+4.8%$1.13+155.7%-63.0%$16.84M$9.78M-0.2690Earnings ReportAnalyst ForecastShort Interest ↓News CoverageDOMHDominari2.0811 of 5 stars$5.49+32.9%N/A+113.6%$59.91M$12.59M-1.424Positive NewsGap DownFBIOFortress Biotech2.3402 of 5 stars$1.72+0.6%$21.00+1,120.9%-13.0%$47.48M$62.50M-0.56170AGENAgenus3.559 of 5 stars$1.64+1.9%$8.75+433.5%-84.4%$41.51M$103.46M-0.15440CRISCuris2.5573 of 5 stars$2.60-2.3%$23.00+784.6%-76.5%$22.01M$10.26M-0.3360Gap UpSABSSAB Biotherapeutics3.5412 of 5 stars$1.60-7.0%$12.40+675.0%-63.3%$14.77M$2.24M0.00140MTEMMolecular Templates0.7674 of 5 stars$0.00+300.0%N/AN/A$3,000.00$23.48M0.00260Gap UpAMGNAmgen4.4603 of 5 stars$314.38-0.5%$314.04-0.1%+8.5%$168.89B$33.42B41.6428,000Positive NewsGILDGilead Sciences4.6071 of 5 stars$106.74-0.3%$104.52-2.1%+50.9%$132.93B$28.75B288.4917,000Positive NewsVRTXVertex Pharmaceuticals3.8865 of 5 stars$511.74+1.7%$506.70-1.0%+19.6%$131.41B$11.02B-232.616,100Positive NewsREGNRegeneron Pharmaceuticals4.8517 of 5 stars$661.00+0.4%$973.13+47.2%-33.6%$72.26B$14.20B17.2711,900Short Interest ↑Positive News Remove Ads Related Companies and Tools Related Companies Dominari Alternatives Fortress Biotech Alternatives Agenus Alternatives Curis Alternatives SAB Biotherapeutics Alternatives Molecular Templates Alternatives Amgen Alternatives Gilead Sciences Alternatives Vertex Pharmaceuticals Alternatives Regeneron Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BOLT) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bolt Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BOLT Stock Free BOLT Stock Alerts